Lonza and Be The Match BioTherapies partner to expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network

Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Lonza announced a strategic partnership to integrate industry-leading solutions in CGT. The goal of the collaboration is to improve efficiency across the CGT supply chain, inclusive of apheresis network management, healthy donor tissue supply, manufacturing and, where appropriate, supply chain management and logistics.

The partnership establishes Be The Match BioTherapies and Lonza as preferred partners and is aimed at supporting the companies’ shared goal of providing end-to-end solutions that streamline the development of cell and gene therapies across the CGT supply chain. Lonza and Be The Match BioTherapies will integrate each other’s services in their respective offerings to provide a seamless offering to customers.

This collaboration builds on current partnerships announced by Lonza and Be The Match BioTherapies to build a seamless, vein-to-vein network for customers and their patients. Partners of Lonza include Cryoport, a leading temperature-controlled supply chain company, and Vineti, a company developing the first commercial, configurable, cloud-based digital platform to orchestrate advanced therapy supply chains. Be The Match BioTherapies brings  expertise in successfully delivering more than 100,000 cell therapies, expertise in logistics, managing apheresis networks, and the ability to provide high-quality cellular source material from the Be The Match Registry which offers the world’s largest, most ethnically diverse listing of more than 22 million potential blood and marrow donors, with Lonza’s industry-leading capabilities in cell and gene therapy manufacturing.